|
Jun 24
|
High Growth Tech Stocks In Europe For June 2025
|
|
Jun 17
|
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
|
|
Apr 24
|
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit
|
|
Apr 24
|
Innate Pharma Announces €15M Investment by Sanofi
|
|
Apr 23
|
Sanofi to Invest $17.2 Million in Innate Pharma as Part of Review of 2016 License Agreement
|
|
Apr 23
|
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company
|
|
Apr 16
|
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
|
|
Apr 16
|
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
|
|
Jan 21
|
Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York
|
|
Jan 16
|
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024
|
|
Sep 30
|
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
|
|
Sep 12
|
Innate Pharma Reports First Half 2024 Business Update and Financial Results
|
|
Sep 9
|
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
|
|
Jul 25
|
Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
|
|
Jan 12
|
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024
|
|
Jan 4
|
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
|
|
Jan 4
|
Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program
|
|
Jan 4
|
Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board
|
|
Dec 19
|
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi
|
|
Dec 18
|
Innate Pharma Announces Leadership Change
|